Fisiopatología del aneurisma de aorta abdominalbiomarcadores y nuevas dianas terapéuticas
- Torres-Fonseca, Monica 1
- Galan, María
- Martinez-Lopez, Diego 1
- Cañes, Laia 2
- Roldan-Montero, Raquel 1
- Alonso, Judit 2
- Reyero-Postigo, Teresa 1
- Orriols, Mar 2
- Mendez-Barbero, Nerea 1
- Sirvent, Marc 3
- Blanco-Colio, Luis Miguel
- Martínez, José 2
- Martin-Ventura, Jose Luis
- Rodríguez, Cristina 2
- 1 Vascular Research Lab, Instituto de Investigación Sanitaria, Hospital Universitario Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, España
- 2 CIBER de Enfermedades Cardiovasculares (CIBERCV), España
- 3 Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España
ISSN: 0214-9168, 1578-1879
Ano de publicación: 2019
Volume: 31
Número: 4
Páxinas: 166-177
Tipo: Artigo
Outras publicacións en: Clínica e investigación en arteriosclerosis
Resumo
Abdominal aortic aneurysm (AAA) is a vascular pathology with a high rate of morbidity and mortality and a prevalence that, in men over 65 years, can reach around 8%. In this disease, usually asymptomatic, there is a progressive dilatation of the vascular wall that can lead to its rupture, a fatal phenomenon in more than 80% of cases. The treatment of patients with asymptomatic aneurysms is limited to periodic monitoring with imaging tests, control of cardiovascular risk factors and treatment with statins and antiplatelet therapy. There is no effective pharmacological treatment capable of limiting AAA progression or avoiding their rupture. At present, the aortic diameter is the only marker of risk of rupture and determines the need for surgical repair when it reaches values greater than 5.5 cm. This review addresses the main aspects related to epidemiology, risk factors, diagnosis and clinical management of AAA, exposes the difficulties to have good biomarkers of this pathology and describes the strategies for the identification of new therapeutic targets and biomarkers in AAA.